Kye Pharmaceuticals, Inc. ("Kye") announced today it has submitted a New Drug Submission (NDS) to Health Canada for the ...

Kye Pharmaceuticals announced it has submitted a New Drug Submission, or NDS, to Health Canada for the regulatory review and approval of ...

Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Canada, Kye Pharmaceuticals, has announced that Health Canada has accepted ...

Dario Eklund, CEO of Santhera said: "The last 12 months have been a pivotal period for both the Company and DMD patients, as we began the global commercial roll-out of AGAMREE. Today, we are ...

AGAMREE, which is already approved and available in the United States, could become the first authorized DMD treatment in Canada if approved. The drug, a corticosteroid designed to maintain efficacy ...

is pleased that Health Canada has granted Priority Review for AGAMREE ® (vamorolone). While corticosteroids have been a key treatment for decades, they are not currently approved for DMD ...

Dario Eklund, CEO of Santhera said : "The last 12 months have been a pivotal period for both the Company and DMD patients, as we began the global commercial roll-out of AGAMREE. Today, we are ...

(CNW Group/Kye Pharmaceuticals Inc.) "Muscular Dystrophy Canada (MDC) is pleased that Health Canada has granted Priority Review for AGAMREE ® (vamorolone). While corticosteroids have been a key ...

Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the ...